Alluvi, known as BI 4744, represents a promising development in obesity therapy. This dual agonist targeting both glucagon-like peptide-1 and GIP receptors demonstrates remarkable efficacy in research assessments, https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/